Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia

• Status: Enrolling by invitation
• Trial end date: 2023-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the effect of lanthanum carbonate and calcium carbonate on the progression of coronary calcification and vascular endothelial dysfunction.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Osaka University
• Collaborator: Bayer
• Treatments: Calcium; Calcium Carbonate; Calcium, Dietary

Criteria

Inclusion Criteria:

• Hyperphosphatemia (For patients without calcium carbonate, ≥4.5 mg/dL) (For patients with calcium carbonate, ≥4.0 mg/dL)

• With written informed consent

Exclusion Criteria:

• History of cardiac surgery

• With coronary artery stent

• Polycystic kidney disease

• Hypothyroidism

• On treatment with lanthanum carbonate

• History of admission within 3 months

• History of ileus

• Severe liver dysfunction

• Severe gastrointestinal dysfunction

• Allergy to lanthanum carbonate or calcium carbonate

• Pregnant or breastfeeding women

• Judged as ineligible by the investigator